Loading...
Market
Will Eisai and Biogen announce a new Alzheimer's drug by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Eisai or Biogen
Story
CHMP Recommends EU Rejection of Eisai and Biogen's Alzheimer's Drug Leqembi
Jul 26, 2024, 11:19 AM
On July 26, 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on lecanemab, also known as Leqembi, an Alzheimer's therapy developed by Eisai and Biogen, recommending its rejection in the European Union. This decision diverges from the stance of U.S. regulators, who have approved the medicine. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales of the drug in Europe.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Drugmaker A • 25%
Drugmaker B • 25%
Drugmaker C • 25%
None • 25%
